anti human Assay cDNA exosome

anti-THSD7A som diagnostiske serologiske markører for idiopatisk

RebekahLeave a reply

Diagnostisk præstation af præoperativ [ 18 F] FDG-PET / CT til lymfeknudestaging i vulvarcancer: en stor single-center-undersøgelse

Function: This retrospective research aimed to evaluate the diagnostic efficiency of preoperative [18F]FDG-PET/CT in predicting the groin and pelvic lymph node (LN) standing in a big single-centre collection of vulvar most cancers sufferers.
Strategies: Between January 2013 and October 2018, amongst all consecutive ladies with confirmed vulvar most cancers submitted to [18F]FDG-PET/CT, 160 sufferers had been included. LNs had been analysed by two qualitative strategies assessing PET info (outlined as visible evaluation) and a mix of PET and low-dose CT info (outlined as total evaluation), respectively, in addition to semi-quantitative evaluation (LN-SUVmax).
Sensitivity, specificity, accuracy, constructive and detrimental predictive values (PPV and NPV) in predicting the groin and pelvic LN standing had been calculated within the total research inhabitants; a subset evaluation of groin parameters in clinically/ultrasonography detrimental sufferers was additionally carried out. Histopathology was the reference customary.
Outcomes: All sufferers underwent vulvar and inguinofemoral LN surgical procedure, and 35 pelvic LN surgical procedure. General, 338 LN websites (296 groins and 42 pelvic websites) had been histologically examined with 30.4% prevalence of metastatic groins and 28.6% for metastatic pelvic websites.
Within the total research inhabitants, sensitivity (95% confidence interval, CI), specificity (95% CI), accuracy (95% CI), PPV (95% CI) and NPV (95% CI) on the groin degree had been 85.6% (78.3-92.8), 65.5% (59.0-72.0), 71.6% (66.5-76.8), 52.0% (44.0-60.1) and 91.2% (86.7-95.8) for visible evaluation; 78.9% (70.5-87.3), 78.2% (72.5-83.8), 78.4% (73.7-83.1), 61.2% (52.3-70.1) and 89.4% (85.0-93.9) for total evaluation; and 73.3% (64.2-82.5), 85.0% (80.1-89.8), 81.4% (77.0-85.8), 68.0% (58.8-77.3) and 87.9% (83.4-92.5) for semi-quantitative evaluation (SUVmax cut-off worth 1.89 achieved by ROC evaluation). Comparable outcomes had been noticed within the pelvis-based evaluation.
Conclusion: On this giant single-centre collection of vulvar most cancers sufferers, [18F]FDG-PET/CT confirmed good values of sensitivity and NPV in discriminating metastatic from non-metastatic LNs. In routine medical observe, qualitative evaluation is a dependable interpretative criterion making pointless generally used semi-quantitative strategies resembling SUVmax.
Key phrases: Lymph node staging; Customized medication; Vulvar most cancers; [18F]FDG-PET/CT.

Anti-PLA2R og anti-THSD7A som diagnostiske serologiske markører for idiopatisk membranøs nefropati: En enkelt centerundersøgelse

Idiopathic Membranous Nephropathy (IMN) is a renal-limited autoimmune illness and accounts for roughly 80% of MNs. This research aimed to guage the position of circulating Anti-PLA2R and anti-THSD7A autoantibodies within the analysis and differentiation between main and secondary MN. This research was performed on 58 grownup sufferers with biopsy-proven membranous glomerulopathy (MGN).
All had been subjected to measurement of Anti-PLA2R1 by an Enzyme-Linked Immunosorbent Assay and anti-THSD7A was detected by an oblique immunofluorescence assay. Among the many 58 sufferers, 79.3% had been identified as IMN, and 20.7% as secondary membranous glomerulopathy (SMN).
Amongst IMN sufferers, 32 sufferers (69.6%) confirmed constructive anti-PLA2R1 antibodies, 2 sufferers (4.3%) had been constructive for anti-THSD7A antibodies and the remaining 12 sufferers (26.1%) had been detrimental for each kinds of antibodies. Sufferers with SMN had been detrimental for the 2 antibodies.
The IMN sufferers had decrease serum creatinine in comparison with the SMN sufferers (P=0.017). In conclusion, the research demonstrates that roughly 70% of sufferers with idiopathic membranous nephropathy have antibodies in opposition to PLA2R indicating that Anti-PLA2R could also be quick, simple, comparatively delicate, and non-invasive check for analysis of IMN.
cidic
cidic

ALT. THIOGLYCOLLATE MED.
A01-103-2Kg 2 Kg Ask for price

ALT. THIOGLYCOLLATE MED.
A01-103-500g 500 g Ask for price

Bouin's Fluid
BNF125 125 ml
EUR 63

Bouin's Fluid
BNF3800 1 Gal.
EUR 178

Bouin's Fluid
BNF500 500 ml
EUR 80

Bouin's Fluid
BNF999 1000 ml
EUR 98

P-Selectin (PF377), RNA Aptamer, unlabeled
AR-298-U Custom Ask for price

Rat Neuromedin U control/blocking peptide # 2
NMU51-P 100 ug
EUR 164

Human Neuromedin U control/blocking peptide # 3
NMU61-P 100 ug
EUR 164

Mouse Neuromedin U control/blocking peptide # 4
NMU71-P 100 ug
EUR 164

Michel's Transport Fluid
MTF-10000 10 L
EUR 762

Michel's Transport Fluid
MTF-20000 20 L
EUR 1340

Michel's Transport Fluid
MTF500 500 ml
EUR 98

Michel's Transport Fluid
MTF999 1000 ml
EUR 127

Ansamitocin P-3
ADC-P-003 unit Ask for price

Neuromedin U (R/M/H) control/blocking peptides
NMU41-P 100 ug
EUR 164

AXYPREP MAG PLASMID KIT- MEDIUM - 384 PREPS
MAG-P-M 1/pk
EUR 664
Description: Bioscience Mag Beads; Magnetic Plasmid

HE4, Human ascites fluid
P1438-100
EUR 620

HE4, Human ascites fluid
P1438-500
EUR 2839

SOF Synthetic Oviduct Fluid.
IVL05-100ML 100 ml
EUR 78
Description: Synthetic Oviduct Fluid.

SOF Synthetic Oviduct Fluid.
IVL05-6X100ML 6 x 100 ml
EUR 151
Description: Synthetic Oviduct Fluid.

96-Well, pureGrade, Clear Transparent, U-Bottom, 5 Plates/Sleeve, 100/Unit
33-572X 100 plates
EUR 240
Description:
  • Clear for colorimetric assays
  • Non-treated "medium binding" surface
  • 100% high quality polystyrene
  • 330µl well volume
  • Non-sterile
  • 1 lid included in each stack (20 total lids)
  • 20 stacks of 5 plates, pack of 100

Transparent, 96-Well Plates, pureGrade Sterile, Clear U-Bottom 50 Plates/Unit
91-420U 50 plates
EUR 230
Description:
  • Non-treated medium binding surface
  • 100% high quality polystyrene
  • Individually-wrapped plates w/ lids
  • Sterilized via beta-radiation
  • Available in clear, white or black
  • Free from endotoxins, DNase, DNA, RNase; noncytotoxic

Calci-Clear
NAT1312 EACH
EUR 78

Calci-Clear
NAT1314 EACH
EUR 128

Calci-Clear
NAT1316 EACH
EUR 386

Histo-Clear
NAT1330 1 US gallon
EUR 154

Histo-Clear
NAT1332 5 US gallons
EUR 583

Hepatitis B Virus (HBV) Polymerase (P protein) (A9), RNA Aptamer, unlabeled
AR-233-U Custom Ask for price

Mouse p/CIP/p300 Control/blocking peptide # 1
CIP11-P 100 ug
EUR 164

Mouse p/CIP/p300 Control/blocking peptide # 2
CIP12-P 100 ug
EUR 164

YLKKIKNSL, P. falciparum circumsporozoite (CSP 334-342) polypeptide
CSPF15-P 1 mg
EUR 286

MICROPLATE, 96 WELL, POLYSTYRENE, CLEAR, ROUND BOTTOM, MEDIUM BINDING, NO LID, NONSTERILE, BULK
3797 25/pk
EUR 179
Description: Assay; EIA/RIA - 96 Well

CA-125, Human Ascites Fluid
P1446-10
EUR 294

Human Substance P Peptide (amide salt)
SP15-P-1 1 mg
EUR 164

Human Substance P Peptide (amide salt)
SP15-P-25 25 mg
EUR 529

Human Substance P Peptide (amide salt)
SP15-P-5 5 mg
EUR 286

LEYYLREKAKMAGTLIIPES, P. vivax PvMSP-1 peptide 19 (378-397)
MSPV11-P 1 mg
EUR 164

SKDQIKKLTSLKNKLERRQN, P. vivax PvMSP-1 peptide 53 (1058-1077)
MSPV12-P 1 mg
EUR 164

NFVGKFLELQIPGHTDLLHL, P. vivax PvMSP-1 peptide 4 (78-97)
MSPV13-P 1 mg
EUR 164

FNQLMHVINFHYDLLRANVH, P. vivax PvMSP-1 peptide 6 (118-137)
MSPV14-P 1 mg
EUR 164

LDMLKKVVLGLWKPLDNIKD, P. vivax PvMSP-1 peptide 8 (158-177)
MSPV15-P 1 mg
EUR 164

U-104
9631-25
EUR 414

U-104
9631-5
EUR 142

U-18666A
9469-100 Ask for price

U-18666A
9469-25
EUR 457

U-18666A
9469-5
EUR 153

Kazinol U
TBW00590 unit Ask for price

Gomisin U
TBW01615 5mg Ask for price

Ixerin U
TBZ1502 unit Ask for price

U-93631
B1851-25
EUR 544

U-93631
B1851-5
EUR 175

U-73122
B1887-25
EUR 544

U-73122
B1887-5
EUR 175

U-73343
B1888-5
EUR 175

U-74389G
20-abx076631
  • EUR 314.00
  • EUR 857.00
  • 100 mg
  • 500 mg

U-0126
20-abx076796
  • EUR 1121.00
  • EUR 384.00
  • 25 mg
  • 5 mg

U-101017
HY-19250 1mg
EUR 1125

U-73343
HY-108630 5mg
EUR 234

U-73122
HY-13419 10mM/1mL
EUR 147

U-104
HY-13513 10mM/1mL
EUR 113

U 0126
E1B1901 1mg
EUR 161

U-44069
C5324-1 1 mg
EUR 224
Description: EC50: 3 ?M and 54 nM for platelet aggregation and phosphatidate formation in human platelets, respectivelyU-44069 is a TP receptor agonist.

U-44069
C5324-10 10 mg
EUR 1442
Description: EC50: 3 ?M and 54 nM for platelet aggregation and phosphatidate formation in human platelets, respectivelyU-44069 is a TP receptor agonist.

U-44069
C5324-5 5 mg
EUR 833
Description: EC50: 3 ?M and 54 nM for platelet aggregation and phosphatidate formation in human platelets, respectivelyU-44069 is a TP receptor agonist.

U 90042
B7164-10 10 mg
EUR 350

U 90042
B7164-50 50 mg
EUR 1266

U 89843A
B7165-10 10 mg
EUR 292

U 89843A
B7165-50 50 mg
EUR 1054

U 93631
B7170-10 10 mg
EUR 248

U 93631
B7170-100 100 mg
EUR 1407

U 93631
B7170-5 5 mg
EUR 195

U 93631
B7170-5.1 10 mM (in 1mL DMSO)
EUR 209

U 93631
B7170-50 50 mg
EUR 864

U 73343
B9013-10 10 mg
EUR 224

U 73343
B9013-25 25 mg
EUR 441

U 73343
B9013-5 5 mg
EUR 154

U-104
A4358-10 10 mg
EUR 108
Description: U-104 is a novel ureido-sulfonamide inhibitor of Carbonic Anhydrase IX (CAIX). Tumor volume measurements show important inhibition of primary tumor growth in the mice treated with the U-104 compound compared with vehicle controls

U-104
A4358-25 25 mg
EUR 171
Description: U-104 is a novel ureido-sulfonamide inhibitor of Carbonic Anhydrase IX (CAIX). Tumor volume measurements show important inhibition of primary tumor growth in the mice treated with the U-104 compound compared with vehicle controls

U-104
A4358-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: U-104 is a novel ureido-sulfonamide inhibitor of Carbonic Anhydrase IX (CAIX). Tumor volume measurements show important inhibition of primary tumor growth in the mice treated with the U-104 compound compared with vehicle controls

U-104
A4358-50 50 mg
EUR 270
Description: U-104 is a novel ureido-sulfonamide inhibitor of Carbonic Anhydrase IX (CAIX). Tumor volume measurements show important inhibition of primary tumor growth in the mice treated with the U-104 compound compared with vehicle controls

U-73122
B3422-10 10 mg
EUR 161
Description: U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

U-73122
B3422-25 25 mg
EUR 258
Description: U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

U-73122
B3422-5 5 mg
EUR 123
Description: U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

U-73122
B3422-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

U 18666A
B6812-10 10 mg
EUR 150
Description: U 18666A is an inhibitor of cholesterol transport and synthesis [1] [2]. Cholesterol is a sterol that biosynthesized by all animal cells and is an essential component of all animal cell membranes that is required to maintain membrane fluidity and structural integrity.

U 18666A
B6812-25 25 mg
EUR 287
Description: U 18666A is an inhibitor of cholesterol transport and synthesis [1] [2]. Cholesterol is a sterol that biosynthesized by all animal cells and is an essential component of all animal cell membranes that is required to maintain membrane fluidity and structural integrity.

U 18666A
B6812-50 50 mg
EUR 473
Description: U 18666A is an inhibitor of cholesterol transport and synthesis [1] [2]. Cholesterol is a sterol that biosynthesized by all animal cells and is an essential component of all animal cell membranes that is required to maintain membrane fluidity and structural integrity.

U 46619
B6890-1 1 mg
EUR 147
Description: EC50: 0.035 ?M for shape change, 0.057 ?M for MLCP, 0.536 ?M for serotonin release, 1.31 ?M for aggregation.

U 46619
B6890-10 10 mg
EUR 830
Description: EC50: 0.035 ?M for shape change, 0.057 ?M for MLCP, 0.536 ?M for serotonin release, 1.31 ?M for aggregation.

U 46619
B6890-5 5 mg
EUR 487
Description: EC50: 0.035 ?M for shape change, 0.057 ?M for MLCP, 0.536 ?M for serotonin release, 1.31 ?M for aggregation.

EC MEDIUM
E05-100-10kg 10 kg
EUR 814

EC MEDIUM
E05-100-2Kg 2 Kg
EUR 216

EC MEDIUM
E05-100-500g 500 g
EUR 95

COLIFORM MEDIUM
C03-127-10kg 10 kg
EUR 1324

COLIFORM MEDIUM
C03-127-2kg 2kg
EUR 327

COLIFORM MEDIUM
C03-127-500g 500 g
EUR 125

HLP MEDIUM
H08-107-10kg 10 kg
EUR 2278

HLP MEDIUM
H08-107-2Kg 2 Kg
EUR 534

HLP MEDIUM
H08-107-500g 500 g
EUR 182

VALI Medium
450 500 ml
EUR 265

DC MEDIUM
D04-117-10kg 10 kg
EUR 1579

DC MEDIUM
D04-117-2kg 2kg
EUR 382

DC MEDIUM
D04-117-500g 500 g
EUR 140

SIM MEDIUM
S19-110-10kg 10 kg
EUR 1021

SIM MEDIUM
S19-110-2kg 2kg
EUR 261

SIM MEDIUM
S19-110-500g 500 g
EUR 107

SOB MEDIUM
S19-124-10kg 10 kg
EUR 965

SOB MEDIUM
S19-124-2kg 2kg
EUR 249

SOB MEDIUM
S19-124-500g 500 g
EUR 104

Advanced Medium
C0003-04 RT 500 mL Bottle
EUR 103

Medium 199
C0012-01 RT 500 mL Bottle
EUR 105

NeuroProgenitor Medium
NM42400 125 ml
EUR 304

Anvendelse af tørrede rørprøver af Plasmodium falciparum i et eksternt kvalitetsvurderingsprogram til evaluering af sundhedsarbejderes ydeevne til hurtig diagnostisk check af malaria i sundhedscentre i Togo

Background: The usage of speedy diagnostic exams (RDTs) to diagnose malaria is widespread in sub-Saharan African laboratories, distant main well being amenities and locally. At the moment, there’s a lack of dependable strategies to establish well being employee competency to precisely use RDTs within the testing and analysis of malaria.
Dried tube specimens (DTS) have been proven to be a constant and helpful methodology for high quality management of malaria RDTs; nevertheless, its software in Nationwide High quality Administration programmes has been restricted.
Strategies: A Plasmodium falciparum pressure was grown in tradition and harvested to create DTS of various parasite density (0, 100, 200, 500 and 1000 parasites/µL). Utilizing the dried tube specimens as high quality management materials, a proficiency testing (PT) programme was carried out in 80 consultant well being centres in Togo.
Well being employee competency for performing malaria RDTs was assessed utilizing 5 blinded DTS samples, and the DTS had been examined in the identical method as a affected person pattern could be examined by a number of testers per well being centre.
Outcomes: All of the DTS with 100 parasites/µl and 50% of DTS with 200 parasites/µl had been labeled as non-reactive through the pre-PT high quality management step. Due to this fact, knowledge from these parasite densities weren’t analysed as a part of the PT dataset.
PT scores throughout all 80 amenities and 235 testers was 100% for Zero parasites/µl, 63% for 500 parasites/µl and 93% for 1000 parasites/µl. General, 59% of the 80 healthcare centres that participated within the PT programme acquired a rating of 80% or increased on a set of 0, 500 and 1000 parasites/ µl DTS samples. Sixty % of well being employees at these centres recorded right check outcomes for all three samples.
Conclusions: The usage of DTS for a malaria PT programme was the primary of its form ever performed in Togo. The benefit of use and stability of the DTS illustrates that one of these samples will be thought of for the evaluation of workers competency. The implementation of high quality administration methods, refresher coaching and expanded PT at distant testing amenities are important components to enhance the standard of malaria analysis.
Key phrases: Malaria; Plasmodium falciparum; Proficiency testing; High quality management; RDT; Togo.
Coronavirus sygdom 2019 strategier, undersøgelsesdetaljer og sikkerhedsprocedurer for diagnostiske radiologifaciliteter: En omfattende multicenter-oplevelse i Istanbul, Tyrkiet
This research aimed to share our experiences through the coronavirus illness 2019 (COVID-19) pandemic obtained in diagnostic radiology amenities of 5 Coaching Analysis Hospitals within the Asian a part of Istanbul (North Hospitals). Accordingly, we reported the utilised examination particulars, allocation of radiology workers and actions and security procedures for sufferers and radiology workers.
As the company radiology group serving in these designated pandemic hospitals, examination particulars and security procedures of some diagnostic radiology amenities amongst 5 coaching analysis hospitals have been recognized within the present research.
Our pointers and preparedness protocol aimed to scale back affected person morbidity and infection-related mortality by fast and correct analysis to stop the unfold of COVID-19 to our staff, sufferers and most people through the COVID-19 pandemic.
Outcomes confirmed that teamwork is a key issue whereas offering medical companies. As well as, steady communication efforts and particular person obligations of radiology workers had been outstanding through the COVID-19 pandemic.
The current scenario additionally confirmed that co-operation of radiology amenities with system producers and applicators are fairly important particularly for improvement of particular protocols within the body of As Low As Fairly Achievable.
The COVID-19 pandemic has tackled a number of challenges in radiology amongst radiology departments. Due to this fact, steady co-operation plans and motivational actions are extremely really useful not solely between radiology workers but additionally between radiology stakeholders and repair suppliers sooner or later.
Technical particulars of current investigation can present helpful details about the administration of diagnostic radiology departments through the combat with the COVID-19 pandemic in cities with excessive inhabitants density resembling Istanbul.

EverBrite Hardset Mounting Medium
23003 10mL
EUR 195
Description: Minimum order quantity: 1 unit of 10mL

EverBrite Mounting Medium with DAPI
23002 10mL
EUR 195
Description: Minimum order quantity: 1 unit of 10mL

FluoreGuard Mounting Medium (Hard Set)
FMH030 30 ml
EUR 96

FluoreGuard Mounting Medium (Hard Set)
FMH060 60 ml
EUR 116

FluoreGuard Mounting Medium (Hard Set)
FMH500 500 ml
EUR 327

FluoreGuard Mounting Medium (Hard Set)
FMH999 1000 ml
EUR 530

Advantage Mounting Media, for permanent mounting and Coverslipping IHC & special stains from water, 60ml
NB300 60 ml
EUR 427

Advantage Mounting Media, for permanent mounting and Coverslipping IHC & special stains from water, 30ml
NB300-30 30 ml
EUR 276

Advantage Mounting Media, for permanent mounting and Coverslipping IHC & special stains from water, 125ml
NB300A 125 ml
EUR 543

FluoroQuest™ Mounting Medium with DAPI
20004 50 mL
EUR 132

Anti-Fade Mounting Medium (With DAPI)
abx090690-10ml 10 ml
EUR 203

Anti-Fade Mounting Medium (With PI)
abx090691-10ml 10 ml
EUR 203

EverBrite Hardset Mounting Medium with DAPI
23004 10mL
EUR 213
Description: Minimum order quantity: 1 unit of 10mL

Mounting Media
99-MED 3 ml
EUR 211
Description: Mounting media for use in microscopy preparations

FluorLast? Mounting Media
1213-20
EUR 142

Buffered Glycerol Mounting Media
GMM003 3 ml
EUR 61

Buffered Glycerol Mounting Media
GMM030 30 ml
EUR 72

Buffered Glycerol Mounting Media
GMM500 500 ml
EUR 183

Buffered Glycerol Mounting Media
GMM999 1000 ml
EUR 260

Permanent Mounting Media (Aqueous)
PMT030 30 ml
EUR 109

Permanent Mounting Media (Aqueous)
PMT999 1000 ml
EUR 759

ReadiUse™ microscope mounting solution
20009 50 mL
EUR 115

PolyMount Mounting Media MaxTag Histo (OKRA00045)
OKRA00045 15 ml
EUR 126
Description: Description of target: ;Species reactivity: ;Application: ;Assay info: ;Sensitivity:

EC MEDIUM
E05-100-10kg 10 kg
EUR 814

EC MEDIUM
E05-100-2Kg 2 Kg
EUR 216

EC MEDIUM
E05-100-500g 500 g
EUR 95

COLIFORM MEDIUM
C03-127-10kg 10 kg
EUR 1324

COLIFORM MEDIUM
C03-127-2kg 2kg
EUR 327

COLIFORM MEDIUM
C03-127-500g 500 g
EUR 125

HLP MEDIUM
H08-107-10kg 10 kg
EUR 2278

HLP MEDIUM
H08-107-2Kg 2 Kg
EUR 534

HLP MEDIUM
H08-107-500g 500 g
EUR 182

VALI Medium
450 500 ml
EUR 265

DC MEDIUM
D04-117-10kg 10 kg
EUR 1579

DC MEDIUM
D04-117-2kg 2kg
EUR 382

DC MEDIUM
D04-117-500g 500 g
EUR 140

SIM MEDIUM
S19-110-10kg 10 kg
EUR 1021

SIM MEDIUM
S19-110-2kg 2kg
EUR 261

SIM MEDIUM
S19-110-500g 500 g
EUR 107

SOB MEDIUM
S19-124-10kg 10 kg
EUR 965

SOB MEDIUM
S19-124-2kg 2kg
EUR 249

SOB MEDIUM
S19-124-500g 500 g
EUR 104

A Medium
DJ1018 100g
EUR 84.8

Advanced Medium
C0003-04 RT 500 mL Bottle
EUR 103

Medium 199
C0012-01 RT 500 mL Bottle
EUR 105

Heller's Medium
CP014-010 10X1L
EUR 99

Heller's Medium
CP014-500 50L
EUR 126

Hoagland's Medium
CP015-010 10X1L
EUR 99

Hoagland's Medium
CP015-500 50L
EUR 126

M9 Medium
SD7024 250g
EUR 71.75

M9CA Medium
SD7025 250g
EUR 71.75

YM Medium
SD7031 250g
EUR 70.45

TYGPN Medium
SD7032 250g
EUR 70.01

M63 Medium
SD7033 250g
EUR 71.75

NeuroProgenitor Medium
NM42400 125 ml
EUR 304

Fine natural hair brush for mounting sections
PO501 each
EUR 67

Insect Cell Medium: TNM-FH Insect Culture Medium
ABP-MED-10001 1 liter Ask for price

Insect Cell Medium: Serum-Free Insect Culture Medium
ABP-MED-10002 1 liter Ask for price

Insect Cell Medium: Grace?s Insect Medium (Unsupplemented)
ABP-MED-10004 1 liter Ask for price

EC MEDIUM, MODIFIED
E05-108-10kg 10 kg
EUR 858

EC MEDIUM, MODIFIED
E05-108-2Kg 2 Kg
EUR 226

EC MEDIUM, MODIFIED
E05-108-500g 500 g
EUR 98

A-1 MEDIUM
A01-116-10kg 10 kg
EUR 1034

A-1 MEDIUM
A01-116-2Kg 2 Kg
EUR 264

A-1 MEDIUM
A01-116-500g 500 g
EUR 108

CARY & BLAIR MEDIUM
C03-131-10kg 10 kg
EUR 2185

CARY & BLAIR MEDIUM
C03-131-2Kg 2 Kg
EUR 514

CARY & BLAIR MEDIUM
C03-131-500g 500 g
EUR 176

FLUID THIOGLYCOLLATE MEDIUM
F06-101-10kg 10 kg
EUR 792

FLUID THIOGLYCOLLATE MEDIUM
F06-101-2kg 2kg
EUR 211

FLUID THIOGLYCOLLATE MEDIUM
F06-101-500g 500 g
EUR 94

TERRIFIC BROTH MEDIUM
T20-114-10kg 10 kg
EUR 675

TERRIFIC BROTH MEDIUM
T20-114-2kg 2kg
EUR 186

TERRIFIC BROTH MEDIUM
T20-114-500g 500 g
EUR 87

THIOGLYCOLLATE MEDIUM, BREWER
T20-118-10kg 10 kg
EUR 1364

THIOGLYCOLLATE MEDIUM, BREWER
T20-118-2kg 2kg
EUR 336

THIOGLYCOLLATE MEDIUM, BREWER
T20-118-500g 500 g
EUR 128

2XYT MICROBIAL MEDIUM
X24-102-10kg 10 kg
EUR 614

2XYT MICROBIAL MEDIUM
X24-102-2Kg 2 Kg
EUR 173

2XYT MICROBIAL MEDIUM
X24-102-500g 500 g
EUR 83

OF BASAL MEDIUM
O15-100-10kg 10 kg Ask for price

OF BASAL MEDIUM
O15-100-2kg 2kg Ask for price

OF BASAL MEDIUM
O15-100-500g 500 g Ask for price

MOTILITY TEST MEDIUM
M13-121-10kg 10 kg
EUR 1528

MOTILITY TEST MEDIUM
M13-121-2Kg 2 Kg
EUR 371

MOTILITY TEST MEDIUM
M13-121-500g 500 g
EUR 137

REINFORCED CLOSTRIDIUM MEDIUM
R18-105-10kg 10 kg
EUR 1194

REINFORCED CLOSTRIDIUM MEDIUM
R18-105-2kg 2kg
EUR 299

REINFORCED CLOSTRIDIUM MEDIUM
R18-105-500g 500 g
EUR 118

Sepadextran-25 Medium
SD25M-100 100 g
EUR 271

Sepadextran-25 Medium
SD25M-500 500 g
EUR 1036

Sepadextran-50 Medium
SD50M-100 100 g
EUR 344

Sepadextran-50 Medium
SD50M-500 500 g
EUR 1285
, , , , , , , , , , , , , , , , , , , , , , ,

Post navigation

Leave a Reply

Your email address will not be published.